Langerhans cell histiocytosis (LCH) is a clonal proliferation of CD1a+ and Langerin+ dendritic cells with a spectrum ranging from solitary eosinophilic granuloma to disseminated multisystem disease (Letterer-Siwe). It predominantly affects children aged 5-10 years with male predominance (2:1), with the skull (50%) and femur (20%) being the most common skeletal sites. Characteristic findings include "punched-out" lytic skull lesions, vertebra plana in the spine, and histology showing Langerhans cells with coffee-bean nuclei and Birbeck granules. BRAF V600E mutation is present in 50-60% and is a therapeutic target. Treatment ranges from observation/curettage for unifocal bone disease to chemotherapy for multisystem involvement.

Demographics

Age Distribution:

• Peak Incidence: 5-10 years (80% of cases under 15 years)
• Adult Cases: 20% of all LCH, usually unifocal bone
• Neonatal: Rare, often multisystem involvement
• Median Age: 7 years for skeletal LCH

Gender:

• Male to female ratio: 2:1 overall
• Unifocal disease: Male to female 1.5:1
• Multisystem disease: Male to female 3:1

Incidence:

• Overall: 4-9 cases per million children per year
• Skeletal involvement: 80% of all LCH cases
• Multisystem disease: 20% of LCH cases
• Geographic variation: Higher in Caucasian populations

Anatomical Distribution:

• Skull: 50% (calvarium, temporal bone, orbit)
• Femur: 20% (diaphysis more than metaphysis)
• Ribs: 10% (posterior ribs common)
• Pelvis: 10% (ilium, acetabulum)
• Vertebrae: 7% (vertebra plana, thoracic greater than lumbar)
• Mandible: 5% (loose teeth, gingival swelling)
• Other: 8% (humerus, scapula, clavicle)

Pathogenesis

Molecular Biology:

• BRAF V600E Mutation: Present in 50-60% of LCH cases

  • Activating mutation in MAPK/ERK pathway
  • Higher frequency in multisystem disease (60-70%)
  • Associated with increased recurrence risk
  • Therapeutic target for refractory disease

• MAP2K1 Mutations: 20% of BRAF-negative cases

  • Alternative MAPK pathway activation
  • Similar clinical phenotype to BRAF-mutated LCH

• Other Alterations: RAS pathway mutations, chromosomal abnormalities (rare)

Cellular Origin:

• Clonal proliferation of myeloid dendritic cells
• Cells express CD1a, CD207 (Langerin), S100 protein
• Birbeck granules on electron microscopy (tennis racket appearance)
• Eosinophils, lymphocytes, macrophages in infiltrate

Disease Classification:

Modern Classification (Histiocyte Society):

1. Single-System LCH:

   • Single-site (solitary eosinophilic granuloma)
   • Multiple-site (polyostotic, pulmonary)

2. Multisystem LCH:

   • Without risk organ involvement
   • With risk organ involvement (liver, spleen, bone marrow, lung)

Skeletal Manifestations

Symptoms:

• Localized Pain: 60-70% (worse at night, not relieved by rest)
• Swelling: 50% (soft tissue mass overlying bone lesion)
• Functional Limitation: 30% (limp with lower limb lesions)
• Incidental Finding: 20% (asymptomatic, found on imaging)
• Pathological Fracture: 10-15% (long bone lesions)

Physical Examination:

• Focal tenderness over lesion
• Soft tissue fullness or mass
• Limited range of motion (vertebral or juxta-articular)
• Low-grade fever (30% of cases)
• Regional lymphadenopathy (uncommon)

Site-Specific Presentations:

Skull:

• Palpable defect or "hole" in calvarium
• Scalp swelling (subperiosteal extension)
• Mastoid involvement: Chronic otitis media, external auditory canal polyp
• Orbital involvement: Proptosis, visual disturbance
• "Button sequestrum" on X-ray (central bone fragment)

Vertebrae:

• Back pain with activity
• Thoracic kyphosis (vertebra plana)
• Rarely neurological deficit (less than 5%)
• Complete vertebral collapse possible
• Adjacent disc spaces preserved (key feature)

Long Bones:

• Diaphyseal more than metaphyseal
• Periosteal reaction simulating infection
• Pathological fracture with minor trauma
• "Onion-skin" periosteal layering possible

Mandible:

• Loose teeth, gingival swelling
• "Floating tooth" appearance on X-ray
• Jaw pain, trismus

Systemic Manifestations (Multisystem Disease)

Classic Triad (Hand-Schüller-Christian):

1. Diabetes insipidus (25% of multisystem cases)
2. Exophthalmos (orbital involvement)
3. Lytic skull lesions

Risk Organ Involvement:

• Liver: Hepatomegaly, jaundice, dysfunction (poor prognosis)
• Spleen: Splenomegaly, hypersplenism
• Bone Marrow: Cytopenias, pancytopenia
• Lung: Cough, dyspnea, pneumothorax (usually older children/adults)

Skin:

• Seborrheic dermatitis-like rash (scalp, retroauricular)
• Papular eruption (trunk, groin)
• Present in 30-40% multisystem cases

Other:

• Lymphadenopathy (cervical, axillary)
• Hepatosplenomegaly
• Failure to thrive (disseminated disease)

Imaging

Plain Radiography:

Skull:

• "Punched-out" lytic lesions, well-defined margins
• "Beveled edge" (inner table destruction greater than outer table)
• "Button sequestrum" (central bone fragment)
• "Geographic skull" (multiple coalescent lesions)

Spine:

• Vertebra plana (complete vertebral collapse, pancake vertebra)
• Preserved disc spaces (key to differentiate from infection)
• Isolated vertebral body involvement
• No paraspinal soft tissue mass (vs tumor, infection)

Long Bones:

• Lytic lesion, diaphyseal or metaphyseal
• "Moth-eaten" or permeative bone destruction
• Periosteal reaction (laminated, solid, or "onion-skin")
• Sequestrum formation possible
• Pathological fracture

Advanced Imaging:

MRI:

• T1: Low signal intensity in lesion
• T2: High signal intensity, surrounding marrow edema
• STIR: Bright signal, extensive edema pattern
• Contrast: Marked enhancement (hypervascular)
• Purpose: Define soft tissue extension, spinal canal involvement

CT:

• Superior for cortical bone detail
• Delineate skull base and orbital lesions
• Assess vertebral body integrity
• 3D reconstruction for surgical planning

Nuclear Medicine:

• Bone Scan (Tc-99m): Increased uptake at lesion sites
• PET-CT: Valuable for staging, detecting occult lesions
  • Higher sensitivity than skeletal survey for bone lesions
  • Detects extraskeletal involvement
  • Useful for monitoring treatment response

Skeletal Survey:

• Mandatory for all LCH cases
• AP and lateral skull, spine, pelvis
• AP chest (include ribs)
• AP long bones bilaterally
• Detect multifocal disease (affects prognosis and treatment)

Imaging Key Points:

1. Vertebra plana with PRESERVED disc spaces distinguishes LCH from infection (discitis destroys disc) and metastasis
2. "Beveled edge" skull lesions are highly specific for LCH in children
3. PET-CT more sensitive than skeletal survey for detecting multifocal disease
4. MRI essential if spine lesion to rule out epidural extension or instability

Laboratory Investigations

Baseline Studies:

• CBC: Assess for cytopenias (marrow involvement)
• ESR/CRP: Often elevated but non-specific
• LFTs: Screen for liver dysfunction
• Coagulation: PT/PTT if hepatic involvement
• Renal Function: Baseline before chemotherapy

Specialized Tests:

• Water Deprivation Test: If diabetes insipidus suspected
• Urinalysis: Polyuria, low specific gravity
• Serum and Urine Osmolality: Confirm DI

Staging Investigations:

• Skeletal survey (or PET-CT)
• Chest X-ray/CT (pulmonary involvement)
• Abdominal ultrasound or MRI (liver, spleen)
• Consider bone marrow biopsy if cytopenias

Histopathology

Macroscopic:

• Tan-gray soft tissue
• Granular, friable consistency
• No gross necrosis or hemorrhage

Microscopic Features:

• Langerhans Cells: Large cells with abundant eosinophilic cytoplasm
  • Reniform or "coffee-bean" nuclei (nuclear grooves)
  • Eccentric nuclei with fine chromatin
• Eosinophils: Prominent, may form microabscesses
• Lymphocytes: T-cells, scattered macrophages
• Giant Cells: Occasional multinucleated giant cells
• Necrosis: May be present in active lesions

Immunohistochemistry:

• CD1a: Positive (hallmark, membranous staining)
• Langerin (CD207): Positive (cytoplasmic, more specific than CD1a)
• S100 Protein: Positive (nuclear and cytoplasmic)
• CD68: Variable positivity
• Cytokeratin: Negative (helps exclude carcinoma)

Electron Microscopy (if available):

• Birbeck Granules: "Tennis racket" or "zipper" appearance
• Rod-shaped cytoplasmic inclusions
• Diagnostic but not required (CD1a/Langerin sufficient)

Molecular Testing:

• BRAF V600E: Mutation analysis (paraffin tissue or blood)
• Positive in 50-60% of cases
• Guides targeted therapy decisions
• Higher positivity in multisystem disease

Risk Stratification

Single-System Disease:

• Unifocal Bone (60%): Solitary eosinophilic granuloma

  • Prognosis: Excellent (greater than 90% spontaneous resolution or cure)
  • Treatment: Observation or minimal intervention

• Multifocal Bone (20%): Multiple bone lesions, no soft tissue

  • Prognosis: Good with chemotherapy
  • Treatment: Low-dose chemotherapy if 2 or more lesions

Multisystem Disease (20%):

• Without Risk Organs: Bone + skin, lymph nodes

  • Prognosis: Good (greater than 90% survival)
  • Treatment: Combination chemotherapy

• With Risk Organs: Liver, spleen, marrow involvement

  • Prognosis: Guarded (70-80% survival)
  • Treatment: Intensive chemotherapy protocols

Treatment by Disease Extent

Unifocal Bone Lesion:

Observation:

• Indications: Asymptomatic, non-weight-bearing bone, no structural risk
• Protocol: Clinical and radiographic monitoring every 3-6 months
• Outcome: 50% spontaneous resolution within 1-2 years
• Duration: Until lesion heals or stabilizes

Curettage ± Bone Grafting:

• Indications: Symptomatic pain, weight-bearing bone, structural risk
• Technique: Intralesional curettage, local adjuvant (phenol, H₂O₂), autograft/allograft
• Outcomes: 90% local control, low recurrence (less than 10%)
• Complications: Pathological fracture during healing (5-10%)

Steroid Injection:

• Technique: Intralesional methylprednisolone (80-120 mg)
• Indications: Vertebral lesions, inaccessible sites
• Outcomes: Effective in 70-80%, may require repeat injection
• Benefits: Minimally invasive, accelerates healing

En Bloc Resection:

• Indications: Expendable bones (rib, fibula, clavicle)
• Outcomes: Definitive local control (near 100%)
• Advantage: Tissue diagnosis and cure in single procedure

Radiation Therapy:

• Historical Use: Previously common, now avoided in children
• Current Role: Very limited (refractory cases only)
• Dose: 6-10 Gy if absolutely necessary
• Concerns: Secondary malignancy risk, growth plate damage

Multifocal Bone and Multisystem Disease:

Chemotherapy Protocols:

First-Line (Histiocyte Society LCH-III):

• Vinblastine: 6 mg/m² IV weekly x 6 weeks, then every 3 weeks
• Prednisolone: 40 mg/m² PO daily x 4 weeks, then taper
• Duration: 12 months for multifocal bone, 12-24 months for multisystem

Intensification (Risk Organ Involvement):

• Add Mercaptopurine or Methotrexate
• More frequent dosing schedule
• Extended duration (24 months)

Refractory Disease (Second-Line):

• Cytarabine (Ara-C): High-dose protocols
• Cladribine (2-CDA): 5 mg/m² IV daily x 5 days, monthly cycles
• BRAF Inhibitors: Vemurafenib, dabrafenib (if BRAF V600E+)
• MEK Inhibitors: Trametinib, cobimetinib

Targeted Therapy:

• BRAF V600E Inhibitors: Vemurafenib 20 mg/kg PO BID
  • Indications: Refractory multisystem disease with BRAF mutation
  • Response Rate: 60-70% in salvage setting
  • Toxicity: Rash, photosensitivity, arthralgia
• MEK Inhibitors: For MAP2K1-mutated disease

Special Situations:

Vertebra Plana:

• Observation: Usually spontaneous reconstitution (50-70%)
• Bracing: If kyphotic deformity or instability
• Steroid Injection: Accelerates healing, reduces pain
• Surgery: Very rare (neurological compromise only)
• Reconstitution: Gradual over 2-5 years, often incomplete

Spinal Lesions with Instability/Neurology:

• MRI to assess epidural extension
• Neurosurgical consultation
• Decompression ± stabilization if cord compromise
• Chemotherapy as definitive treatment (surgery adjunct only)

Pathological Fracture:

• Conservative management (cast/splint)
• Lesion usually heals concurrently with fracture
• Surgery rarely needed (non-union, severe displacement)

Surgical Considerations

Indications for Surgery:

1. Diagnostic biopsy (confirm diagnosis)
2. Symptomatic relief (pain, mass effect)
3. Structural instability (pathological fracture risk)
4. Neurological compromise (spinal cord compression)
5. Failed conservative management

Surgical Techniques:

Curettage:

• Approach based on anatomical site
• Thorough curettage of cavity
• Local adjuvant (phenol, hydrogen peroxide)
• Bone grafting (autograft or allograft)
• Prophylactic fixation if structural concern

Vertebral Lesions:

• Usually avoid surgery (steroid injection preferred)
• Decompression only if neurological deficit
• Posterior approach for epidural extension
• Anterior corpectomy rarely needed

Pathological Fracture:

• Closed reduction and casting usually sufficient
• ORIF if unstable fracture pattern
• Curettage at time of fixation (if accessible)

Complications

Diabetes Insipidus (18-25%):

• Mechanism: Hypothalamic-pituitary axis involvement
• Presentation: Polyuria, polydipsia, hypernatremia
• Diagnosis: Water deprivation test, low urine osmolality
• Management: Desmopressin (DDAVP) lifelong
• Risk Factors: Craniofacial bone lesions, multisystem disease

Orthopedic Sequelae:

• Vertebral collapse and kyphosis (10-15%)
• Limb length discrepancy (femoral lesions)
• Pathological fracture malunion/nonunion (rare)
• Joint stiffness (juxta-articular lesions)
• Premature physeal closure (metaphyseal lesions)

Neurocognitive Dysfunction (10-20%):

• Associated with multisystem disease
• Cerebellar involvement (ataxia, dysarthria)
• Behavioral and learning difficulties
• MRI: White matter changes, cerebellar atrophy

Pulmonary Complications:

• Pneumothorax (spontaneous)
• Respiratory failure (diffuse involvement)
• Progressive fibrosis (chronic disease)

Other:

• Hearing loss (temporal bone involvement)
• Dental problems (mandibular lesions)
• Sclerosing cholangitis (liver involvement)
• Growth retardation (pituitary dysfunction)

Prognosis

Unifocal Bone Disease:

• Survival: Near 100%
• Recurrence: 10-20% (usually at same site)
• Spontaneous Resolution: 50% without intervention
• Long-term Sequelae: Minimal (cosmetic deformity rare)

Multifocal Bone Disease:

• Survival: 95-100%
• Disease-Free Survival: 70-80% at 5 years
• Reactivation: 30-40% (new lesions or progression)
• Permanent Disability: 20% (mainly DI, orthopedic)

Multisystem Disease Without Risk Organs:

• Survival: 90-95%
• Reactivation: 40-50%
• Permanent Consequences: 40% (DI, neurocognitive)

Multisystem Disease With Risk Organs:

• Survival: 70-80% (significantly worse if poor initial response)
• Reactivation: 50-60%
• Permanent Sequelae: 60-70%

Prognostic Factors:

Favorable:

• Unifocal bone disease
• Age greater than 2 years
• Single-system involvement
• Good response to initial therapy

Unfavorable:

• Age less than 2 years
• Risk organ involvement (liver, spleen, marrow)
• Poor initial response to chemotherapy (6 weeks)
• Multisystem disease with greater than 3 organs

Infection:

• Osteomyelitis: Fever, elevated WBC/CRP, metaphyseal location
• Discitis: Disc space narrowing (vs preserved in LCH vertebra plana)
• Tuberculous Osteomyelitis: Chronic course, epidemiology
• Differentiation: Blood cultures, bone biopsy, clinical course

Neoplastic:

• Ewing Sarcoma: Diaphyseal, "onion-skin" periosteal reaction, soft tissue mass
• Osteosarcoma: Metaphyseal, sunburst periosteal reaction, elevated ALP
• Metastases: Neuroblastoma (children), carcinoma (adults)
• Lymphoma: Older children/adults, systemic symptoms
• Differentiation: Biopsy, immunohistochemistry

Other Histiocytic Disorders:

• Erdheim-Chester Disease: Adults, bilateral femoral/tibial diaphyseal sclerosis
• Rosai-Dorfman Disease: Massive lymphadenopathy, S100+ CD1a- cells
• Juvenile Xanthogranuloma: Skin lesions, CD68+ CD1a- cells

Metabolic/Other:

• Fibrous Dysplasia: Ground-glass matrix, no Langerhans cells
• Hyperparathyroidism: Brown tumors, elevated PTH, multiple lesions
• Multiple Myeloma: Adults, monoclonal protein, plasma cells on biopsy

Global Epidemiology

• Incidence approximately 4-9 per million children per year; rarer in adults (1-2 per million)
• Peak 1-3 years for multisystem disease; 5-10 years for single-system bone disease
• Slight male predominance (around 1.2-2:1); reported across all populations worldwide
• Bone is the most common organ involved overall (around 80% of paediatric cases)
• Pulmonary LCH in adults is strongly smoking-associated and follows a distinct natural history

Side-by-Side Guidance

Registry & Trial Networks

• Outcome data are driven by international cooperative trials (LCH-I, LCH-II, LCH-III, LCH-IV) rather than implant/arthroplasty registries
• The Histiocyte Society coordinates global protocol enrolment; regional groups (e.g. NACHO in North America, national paediatric oncology groups in Europe) feed shared datasets
• BRAF/MAPK genotyping is increasingly captured prospectively to stratify targeted-therapy use

High- vs Limited-Resource Practice

• High-resource: routine BRAF/MAP2K1 genotyping, PET-CT staging, access to BRAF/MEK inhibitors and cladribine/cytarabine salvage, long-term endocrine/neurocognitive surveillance
• Limited-resource: diagnosis may rest on morphology plus CD1a/S100 where Langerin and molecular testing are unavailable; skeletal survey substitutes for PET-CT; vinblastine + prednisone remains the affordable, effective backbone; targeted agents often inaccessible
• Universal principles: confirm tissue diagnosis, stage for risk organs, avoid radiotherapy in children, and screen lifelong for diabetes insipidus

• Reactive vs neoplastic: the discovery of clonal MAPK mutations (BRAF V600E, MAP2K1) reframed LCH as an inflammatory myeloid neoplasm, yet the prominent inflammatory infiltrate keeps the "neoplasia vs immune dysregulation" debate alive.
• Optimal duration of targeted therapy: BRAF/MEK inhibitors produce rapid responses but disease frequently rebounds on cessation, and the ideal duration, role of combination with chemotherapy, and long-term toxicity in children remain undefined.
• Vertebra plana management: the balance between observation, intralesional steroid and bracing is not standardised; most lesions reconstitute, but predicting the minority that deform is imprecise.
• Neurodegenerative LCH: progressive cerebellar/brainstem neurodegeneration can appear years after apparent cure; its pathogenesis, screening interval, and whether early MAPK-directed therapy prevents it are unresolved.
• Role of PET-CT vs skeletal survey: PET-CT is more sensitive for occult and extraskeletal disease, but cost, radiation and access limit universal use, so staging strategy varies by setting.